Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin
<strong>Background</strong>: Management of multiple sclerosis (MS) is based on the usage of immunosuppressive and immune-modulating medications. Cytokines play an important role in the pathogenesis of MS. <br/><strong>Objective</strong>: To evaluate the effects of rapam...
Main Authors: | Mansour Salehi, Bahram Bagherpour, Vahid Shayghannejad, Farzaneh Mohebi, Rasool Jafari |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2016-06-01
|
Series: | Iranian Journal of Immunology |
Subjects: | |
Online Access: | http://iji.sums.ac.ir/article_16665_f83547dab1399dc9fa70a5c78f7fa04a.pdf |
Similar Items
-
Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
by: Gabriel Arellano, et al.
Published: (2017-06-01) -
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
by: Cabrera-López Cristina, et al.
Published: (2012-11-01) -
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
by: Oreja-Guevara Celia, et al.
Published: (2012-09-01) -
Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
by: Krzysztof Sadowski, et al.
Published: (2022-04-01) -
Use of topical rapamycin in facial angiofibromas in Indian skin type
by: Vishalakshi Viswanath, et al.
Published: (2016-01-01)